Uniphar (UPR.IR) Stock Price
Uniphar Price
Over the last 13 years Uniphar grew revenue by 12.8% annually, reaching 3.07 B EUR. Earnings per share have grown at 27.3% per year over the last 9 years. For Uniphar, the net margin of 1.7% is broadly stable versus 2.5% a few years ago. At today's price the dividend yield works out to roughly 0.49%. The payout ratio is around 10% of earnings. The dividend has grown at 21.8% per year over the past 5 years. The consensus 12-month price target for Uniphar is 4.94 EUR, about 24.2% above where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Uniphar stock price
Uniphar business model & stock analysis
Frequently asked questions about Uniphar
The business model of Uniphar PLC revolves around being a diversified healthcare services provider. Uniphar operates across three divisions, including Commercial & Clinical, Supply Chain & Retail, and Product Access. The Commercial & Clinical division focuses on providing support services to pharmaceutical manufacturers, while the Supply Chain & Retail division specializes in the distribution and retail of pharmaceutical and healthcare products. Lastly, the Product Access division concentrates on the sourcing and distribution of specialty pharmaceuticals. Uniphar PLC aims to deliver innovative and sustainable solutions to the healthcare industry, while offering a wide range of services and products to meet the evolving needs of their customers.
Uniphar PLC is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Uniphar PLC in the market include companies like McKesson, AmerisourceBergen, and Cardinal Health. These companies operate in the same industry as Uniphar, providing pharmaceutical and healthcare distribution services. Other competitors that Uniphar faces in specific segments of its business include Sisk Healthcare, United Drug, and DCC Healthcare. Uniphar PLC competes with these industry players to gain market share and maintain its position in the healthcare and pharmaceutical distribution sector.
Uniphar PLC is a leading healthcare services provider based in Ireland. Established in 1967, the company has a rich history of over 50 years. Initially a wholesale pharmaceutical business, Uniphar expanded its operations to include integrated commercial and clinical services. Today, it offers a comprehensive range of services to the healthcare industry, including supply chain management, retail pharmacy, product licensing, and support services. Uniphar has a strong presence in Ireland and the UK, and its diverse customer base includes hospitals, pharmacies, pharmaceutical manufacturers, and the government. The company's commitment to innovation, reliability, and customer satisfaction has propelled it to become a trusted partner in the healthcare sector.
Some significant milestones achieved by Uniphar PLC include its successful listing on the Euronext Dublin and London Stock Exchanges in July 2019, marking a significant step in its growth and expansion plans. The company has also made strategic acquisitions, such as the acquisition of M3 Medical Limited in 2020, which strengthened its position in the Irish healthcare market. Furthermore, Uniphar PLC has consistently delivered strong financial performance, with revenue and profit growth year after year. Its focus on innovation and developing new capabilities has allowed the company to enhance its offering and provide comprehensive solutions to the healthcare industry.
Uniphar PLC is primarily present in Ireland, the United Kingdom, and the Benelux region. This pharmaceutical and healthcare services company operates across these countries, providing a wide range of services to healthcare providers, manufacturers, and patients. Uniphar PLC's strong presence in these regions allows them to leverage their expertise and network for the benefit of their customers.
Uniphar PLC represents values of integrity, collaboration, innovation, and customer-focus. With a strong corporate philosophy centered around delivering excellence in healthcare, Uniphar is committed to providing high-quality products and services to improve patient outcomes. The company places great emphasis on building trusted partnerships with healthcare professionals and industry stakeholders, enabling them to navigate complex healthcare supply chains effectively. Uniphar's dedication to continuous innovation and adaptability in a rapidly evolving industry sets it apart. By prioritizing customer needs and maintaining a steadfast focus on ethical practices, Uniphar PLC has established itself as a leading player in the healthcare sector.
Analysts currently set an average price target of 4.93 EUR for the Uniphar stock (median: 4.94 EUR), implying +24.0 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Uniphar stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Uniphar to generate revenue of 3.24 B EUR and earnings per share of 0.27 EUR.
The Uniphar share (UPR.IR) is listed on 4 stock exchanges, including: London (UPR.L), Frankfurt (0NR.F), München (0NR.MU).
Uniphar PLC is a leading provider of healthcare solutions and pharmaceutical products in Europe. The company offers a wide range of services and products that meet the medical needs of patients. Uniphar was founded in 1994 and has been a publicly listed company since 2019. The business model of Uniphar is focused on offering a comprehensive range of services and products in various areas of healthcare. The company has different divisions tailored to the needs of its customers. The division "Uniphar Retail Services" specializes in wholesale and retail. The division offers a wide range of retail products, including over-the-counter medications, dietary supplements, medical devices, and cosmetics. Uniphar also works closely with retailers to develop customized solutions for their needs. Uniphar also has a division called "Uniphar Group" that specializes in providing pharmaceutical products to hospitals and clinics. In addition, the division also offers solutions for drug manufacturing and delivery. Through close collaboration with the pharmaceutical industry, the company also offers solutions for the trade of pharmaceutical products. The division "Uniphar Specialty Healthcare" specializes in the distribution of specialized drugs. The company offers a wide range of medical products for the treatment of chronic conditions such as diabetes, cancer, and HIV/AIDS. The division also works closely with healthcare professionals and hospitals to ensure that patients receive the right medications. Uniphar has also developed a digital platform called "Uniphar Connect". This platform allows customers and business partners to access a wide range of products and services offered by Uniphar. The platform also provides efficient order and delivery processing to ensure that customers receive their required products quickly and easily. Overall, Uniphar has a diversified product portfolio and offers a comprehensive range of services tailored to the needs of the healthcare industry. The company has a strong presence in Europe and works closely with its customers and partners to develop customized solutions for their needs. With a strong focus on digital innovation and strategic partnerships, the company is well positioned to be successful in the future.
The expected revenue of Uniphar is 3.24 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Uniphar is 73.09 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Uniphar is currently 14.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Uniphar stock.
The price-to-sales ratio (P/S) of Uniphar is currently 0.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Uniphar stock.
The Eulerpool Quality Score for Uniphar is 5/10.
The ISIN of Uniphar is IE00BJ5FQX74. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Uniphar is A2PNWJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Uniphar is UPR.IR. The ticker symbol is used to trade Uniphar shares on the stock exchange.
Uniphar stock
Uniphar Peer Group
Uniphar Ticker
Uniphar FIGI
All fundamentals and in-depth analysis of Uniphar
Our stock analysis for Uniphar stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Uniphar. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.